GlobeNewswire

Basilea successfully placed 1 million new registered shares, raising gross proceeds of CHF 45.75 million

Share

NOT FOR RELEASE, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE UNLAWFUL

Basel, Switzerland, February 24, 2021

Basilea Pharmaceutica Ltd. ("Basilea" or the “Company") announced today that it has successfully placed 1 million new shares in a private placement to institutional shareholders by way of an accelerated bookbuilding. The net proceeds will be used for i) the clinical development of Basilea’s clinical oncology drug candidates derazantinib and lisavanbulin, ii) pre-clinical research and development activities, and iii) working capital and other general corporate purposes, including investments in or in-licensing of complementary businesses, products or assets.

David Veitch, Chief Executive Officer of Basilea, said: “Through this transaction we have successfully expanded our institutional shareholder base, including leading healthcare funds, and increased our financial flexibility in order to create value through the progression and expansion of our R&D portfolio in our strategic focus areas. In particular, we have gained further flexibility for our most advanced clinical oncology assets, derazantinib and lisavanbulin, following the upcoming key data readouts.”

Basilea placed 1 million new registered shares of CHF 1.00 par value each at CHF 45.75 per new share. The new shares, corresponding to 8.4% of Basilea’s currently issued share capital, will be issued from Basilea’s authorized share capital, excluding subscription rights of existing shareholders. The new shares are expected to be listed and admitted to trading on SIX Swiss Exchange on February 26, 2021. Payment and settlement are expected to take place on or around February 26, 2021. The new shares will rank pari passu with the existing shares.

In connection with the offering, Basilea has agreed to a 150-day lock-up period following the settlement, subject to customary exceptions. Members of the Board of Directors and Management of Basilea have agreed to a 150-day lock-up period following the settlement, subject to customary exceptions.

As a result of the transaction, Basilea updates its financial guidance for 2021. It maintains its revenue and operating loss guidances and increases its guidance relating to cash and investments to approximately CHF 155 - 160 million at year-end 2021.

Cantor Fitzgerald, Credit Suisse and Bryan Garnier acted as Joint Bookrunners in connection with the offering.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the medical needs of patients with cancer and infectious diseases. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. We are conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication constitutes neither an offer to sell nor a solicitation to buy securities referred to in it ("Securities") and it does not constitute a prospectus or a similar notice within the meaning of articles 35 et seqq. or 69 of the Swiss Financial Services Act. The offer and listing of the Securities will be made without the publication of a prospectus in reliance on the exemptions provided in article 36 paragraph 1 letter a and article 38 paragraph 1 letter a of the Financial Services Act.

These materials shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

In particular, these materials are not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933. The Securities have not been and will not be registered. There will be no public offering of these Securities in the United States.

This communication does not constitute an "offer of securities to the public" within the meaning of Regulation 2017/1129 of the European Union (the "EU ProspectusRegulation") or the EU Prospectus Regulation as it forms part of UK domestic law by virtue of the UK European Union (Withdrawal) Act 2018 (the "UK ProspectusRegulation") of the Securities in any member state of the European Economic Area (the "EEA") or in the UK. Any offers of the Securities to persons in the EEA or in the UK will be made pursuant to exemptions under the EU Prospectus Regulation and the UK Prospectus Regulation from the requirement to produce a prospectus for offers of the Securities.

In member states of the EEA, this communication is being distributed only to, and is directed only at “qualified investors” within the meaning of Article 2(e) of the EU Prospectus Regulation (“Qualified Investors”).

In the United Kingdom, this communication is being distributed only to, and is directed only at “qualified investors” within the meaning of Article 2(e) of the UK Prospectus Regulation who are also (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (b) high net worth entities, or (c) other persons to whom it may otherwise lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevantpersons").

Any investment or investment activity to which this communication relates is available only to Qualified Investors in the EEA and to relevant persons in the United Kingdom and will be engaged in only with Qualified Investors in the EEA and with relevant persons in the United Kingdom. Any person who is not a Qualified Investor or a relevant person, as appropriate, should not act or rely on this communication or any of its contents.

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations
Phone+41 61 606 1102
E-mailmedia_relations@basilea.com
investor_relations@basilea.com

This press release can be downloaded from www.basilea.com.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Prosafe SE: Safe Boreas to provide accommodation support at Buzzard27.2.2021 14:07:30 CETPress release

Prosafe has signed a contract with CNOOC Petroleum Europe Limited for the charter of the Safe Boreas to provide gangway connected operations supporting the Buzzard platform complex in the UK sector of the North Sea. The firm duration of the contract commencing mid-April 2021 is 100 days with three 30-day options. The Safe Boreas will perform the gangway connected work scope using dynamic positioning, providing CNOOC Petroleum Europe Limited flexibility in operation. Total value of the contract excluding the option periods is approximately USD 8.5 million. Jesper Kragh Andresen, CEO of Prosafe says: "The Safe Boreas will strive to offer CNOOC the highest level of service. The Safe Boreas has operated extensively in the UKCS and will provide the safest working environment." Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com Stavanger

Mandalay Resources Corporation tillkännager resultatrapporten för fjärde kvartalet och helåret 202027.2.2021 08:53:04 CETPressemelding

TORONTO, Feb. 27, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) är glada över att tillkännage resultatrapporten för fjärde kvartalet och helåret som slutade den 31 december 2020. Bolagets konsoliderade finansiella resultat för året som slutade 31 december 2020, tillsammans med ledningens diskussion och analys (”MD&A”) för motsvarande period, finns tillgängliga under bolagets profil på www.sedar.com och på bolagets webbplats www.mandalayresources.com. Alla valutor i detta pressmeddelande avser US-dollar om inget annat är angivet. Höjdpunkter för fjärde kvartalet 2020: Intäkter på 45,3 miljoner USD;Justerad EBITDA på 25,3 miljoner USD, tredje högsta kvartalsresultatet i bolagets historia;Konsoliderat nettoresultat på 14,7 miljoner USD eller 0,16 USD per aktie; ochJusterat nettoresultat på 12,1 miljoner USD eller 0,13 USD per aktie. Höjdpunkter för helåret 2020: Intäkter på 179,0 miljoner USD, högsta helårsresultatet sedan 20

Annual financial report 202027.2.2021 08:00:00 CETPress release

FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: Anne Sophie Pijcke, directeur, aspijcke@financiere-tubize.be Annual financial report 2020 Regulated information 27 February 2021 The board of directors of Financière de Tubize has established the 2020 annual financial report. This report is available on the website www.financiere-tubize.be Dividend received from UCB: € 84,4 million (against € 82.4 million in 2019) Profit of € 81,0 million (against € 80.0 million in 2019)Decrease of outstanding debt from € 86.5 million at 31 December 2019 to € 33,5 million at 31 December 2020. If the general shareholders meeting of 30 April 2021 approves the 2020 annual accounts, including the proposed result appropriation, a dividend of € 0,68 will be payable as from 6th of May 2021 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 16. Ex-dividend 4 May 2021 Record date 4 May 2021 Payment date 6 May 2021 In addition, the company Other Lo

Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany26.2.2021 18:30:00 CETPress release

Special approval from German Federal Institute for Drugs and Medical Devices (BfArM) enables home use of a SARS-CoV-2 Rapid Antigen Test using a simple nasal swabThe test will be widely available in pharmacies across Germany Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) to offer the SARS-CoV-2 Rapid Antigen Test using a simple nasal swab for patient self-testing in Germany. The test is a reliable rapid test for the qualitative detection of a specific SARS-CoV-2 antigen in nasal swab samples.This rapid antigen test collects the sample from the front area of the nose instead of the nasopharynx, resulting in a simplified and more comfortable sampling procedure. By following simple instructions, patients can perform the test at home with results ready after only 15 minutes. The test will be made available in pharmacies and requires no prescription. The G

Cargotec Corporation: Share Repurchase 26.2.202126.2.2021 17:40:00 CETPress release

CARGOTEC CORPORATIONANNOUNCEMENT26.2.2021CARGOTEC CORPORATION: SHARE REPURCHASE 26.2.2021In the Helsinki Stock ExchangeTrade date26.2.2021Bourse tradeBuyShareCGCBVAmount40,362SharesAverage price/ share43.7441EURTotal cost1,765,599.36EURCargotec Corporation now holds a total of 300 531 sharesincluding the shares repurchased on 26.2.2021On behalf of Cargotec CorporationNordea Bank OyjJanne SarvikiviSami HuttunenFor further information, please contact:Mikko Puolakka, Executive Vice President and CFOtel. +358 20 777 4105Hanna-Maria Heikkinen, Vice President, Investor Relationstel. +358 20 777 4084www.cargotec.fi Attachment CGCBV_26.2_trades

Leasinvest Real Estate SCA sells the semi-industrial part of the Brixton Business Park in Zaventem26.2.2021 17:40:00 CETPress release

Today the deed has been executed regarding the sale of the semi-industrial part of the Brixton Business Park in Zaventem, as already announced in the latest press release regarding the 2020 annual results. The buyer is an affiliate of Exeter Property Group. Knight Frank acted as the broker in this transaction. The Brixton Business Park comprises 5 semi-industrial buildings with a total area of 18,788 sqm. This divestment is fully in line with the strategy of Leasinvest, which is aimed at selling non-strategic properties and focusing on new sustainable projects. The current favorable market situation enabled a successful sale of this type of property. This divestment also has favorable financial effects: not only does the debt ratio now reduce to the targeted level of less than 55%, the realized capital gain on this transaction has also allowed Leasinvest to expedite the reimbursement of part of our derivatives portfolio, thus further reducing the average financing cost following the ea

Incap Corporation: THE BOARD OF DIRECTORS OF INCAP HAS RESOLVED ON PAYING A PART OF THE PURCHASE PRICE PAYABLE TO THE SELLERS OF AWS ELECTRONICS GROUP IN NEW SHARES OF INCAP CORPORATION26.2.2021 16:30:00 CETPress release

INCAP CORPORATION STOCK EXCHANGE RELEASE 26 February 2021 at 5.30 p.m. (EET) THE PURCHASE OF AWS ELECTRONICS GROUP Incap Corporation (the “Company” or “Incap”) announced on 23 January 2020 that it has signed an agreement to acquire the entire share capital of AWS Electronics Group (“AWS”). The group has been included in Incap Group’s reporting as of 23 January 2020. The debt-free purchase price was 13.5 million pounds (then approximately EUR 15.9 million), and the additional purchase price amounted to EUR 0.6 million. The acquisition was financed with a loan of EUR 13 million and paid in cash, with the exception of an instalment of 0.6 million pounds to be paid in Incap shares. A PART OF THE PURCHASE PRICE The Board of Directors of the Company has on 26 February 2021 resolved, that the sellers of AWS will be paid an equivalent of 600,000 pounds in new shares of the Company in a directed share issue with payment (the “Share Issue”). The Share Issue will be consummated on 26 February 202